Antibody Humanization And Optimization Service


  1. Detailed sequence analysis and 3D structure modeling
  2. Identification of the best human germline sequence templates, grafting the rodent or rabbit antibody CDR regions into the human antibody frameworks
  3. Identifying back-mutations and remove “hot spots” with developability issues
  4. High throughput lead selection and evaluation
  5. Efficient lead preparation for research purpose in house (up to 20mg), CMC level protein preparation at the facility of our CMC partner (http://www.mabventure.com/en/about.php)

Antibody humanization and optimization workflow:



  1. Fv modeling
    • Application of Schordinger to build up one Fv homology model and one Fv hetero model
    • Generate aggregation surface report
    • Generate PTM analysis report (including N-glycosylation, deamidation, oxidation and protease site analysis based on the displaying status of the amino acid on 3D structure surface)
    • Generate 3D PI prediction
  2. Humanization and optimization design
    • Up to 5 humanized VH and 5 humanized VL versions will be designed respectively
    • PTMs will be removed if antibody’s affinity and/or developability won’t be significantly affected
    • Change of 3D PI and aggregation potential will be marked during the design process, if developability issue is observed on bench, these Information will be applied to fix the developability problem of the humanization lead
    • Predicted high risk T-cell epitope, B cell epitope, MHC-II epitope and antigenicity epitope will be recorded. Clients will be informed about the potential complications to remove these epitopes
  3. First round of leads selection and production
    • DNA synthesis, cloning and transient transfection
    • Affinity (ELISA) assay with expression media
    • Aggregation potential and thermos-stability raw screening (ELISAs after heating) with expression media
    • Production of top 3 humanization leads and chimeric antibody (2mg each)
    • Non-specific binding assay (ELISA on Baculovirus) with in-house controls
  4. Second round of final humanization lead selection (from first round leads)
    • Affinity: Probelife (similar to Octect for detecting kd) or cell based assay (such as FACS, if other methods are not applicable)
    • Aggregation potential: DLS
    • Thermostability: DSF
    • Purity: CE


Price list, payment method and time line:



Significant discounts will be applied for start-ups and/or multiple projects!



Package A: Golden Design ($30,000)



No.1 + No.2


Upfront payment: $20,000


Design fee payment: $10,000



Design starts after receiving the upfront payment ($20,000), 2 weeks after receiving the payment, an antibody humanization report include:


  • Fv models
  • Schordinger aggregation surface prediction
  • Schordinger PTM analysis
  • 3D based PI prediction
  • Human template information
  • Humanization percentage of each VH and VL version
  • Optimization interpretation
  • List of predicted high risk T-cell epitopes, B-cell epitopes, MHC-II epitopes and antigenicity epitopes will be sent to the client


If the client is satisfied with the report, please pay the remaining service fee ($10,000) in two weeks. After receiving the final payment, sequences of all humanized VH and VL versions will be sent to the client via email in 2 days. If needed, the designer will provide clients free email consultation service within 2 months after the sequences are received by the client.



Package B: Gold design + Preliminary screening ($60,000)



No.1 + No.2 + No.3


Upfront payment: $20,000


Design fee payment: $10,000



Golden design service starts after receiving $20,000 upfront payment. Design report (without sequence information) will be sent to customer in 2 weeks. Preliminary screening will be performed after clients approve the design and pay the $15,000 service fee. Preliminary screening data will be sent to clients in 6 weeks without second round of sequence optimization for affinity (~ 90% frequency) or 10 weeks with second round of sequence optimization for affinity (~ 10% frequency). One week after the data is received and approved by the client, $10,000 remaining design fee and $15,000 protein production, purification and characterization fee needs to be sent to Ab Studio. After receiving the final payment, Ab Studio will send to client humanized sequences information, 2mg of purified chimeric antibody and 3 leading humanized antibodies, as well as antigen binding data (ELISA), non-specific binding data (Baculovirus ELISA) to the client in 6 weeks.



Package C: Diamond full humanization service ($90,000)



No.1 + No.2 + No.3 + No.4


Upfront payment: $20,000


Preliminary screening payment: $30,000


Design fee payment: $10,000


Secondary round screening payment: $20,000


Leading IgG production and characterization payment: $10,000



Humanization and optimization design starts after receiving $20,000 upfront payment, design report without sequence information will be sent to client for approval in 2 weeks. Preliminary screening will start after clients approve the design and pay the $15,000 service fee. Preliminary screening data will be sent to clients in 6 weeks without second round of sequence optimization for affinity (~ 90% frequency) or 10 weeks with second round of sequence optimization for affinity (~ 10% frequency). After the data is received and approved by the client, $35,000 protein production, purification and second round screening fee needs to be sent to Ab Studio. After receiving the payment, Ab Studio will start the secondary round screening service which will take 8 weeks without further sequence optimization for developability (~80% frequency) or 12 weeks with further sequence optimization for developability (~20% frequency). The data from the second round of screening will be sent to client for selecting the final lead sequence. Once the client informs Ab Studio the final lead and sends us $10,000 lead production fee as well as $10,000 remaining design fee, Ab Studio will purify 10mg of the final lead antibody protein and send it to client along with the remaining purified antibodies from first round screening as well as the full antibody humanization/optimization report (containing all designed sequences).